Literature DB >> 15966506

Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome.

G Marchesini1, S Avagnina, E G Barantani, A M Ciccarone, F Corica, E Dall'Aglio, R Dalle Grave, P S Morpurgo, F Tomasi, E Vitacolonna.   

Abstract

Fatty liver at ultrasounds, with/ without raised plasma levels of hepatic enzymes, is common in obesity. In most cases, it is the hallmark of non-alcoholic fatty liver disease (NAFLD), a potentially progressive disease associated with insulin resistance and the metabolic syndrome (MS). We tested the hypothesis that insulin resistance per se might be associated with hepatocellular necrosis. Alanine and aspartate aminotransferases (ALT and AST; no.=799) and gamma-glutamyltranspeptidase (GGT; no.=459) were analyzed in a group of treatment-seeking obese patients recruited in 12 Italian medical centers. Insulin resistance was calculated by the homeostasis model assessment method (HOMA-IR; no.=522). Median ALT and AST increased with increasing obesity class (p=0.001 and p=0.005) and exceeded normal limits in 21.0% of cases. Also HOMA-IR increased with the obesity class (p<0.0001), and was higher in subjects with elevated ALT (median, 4.93 vs 2.89; p<0.0001). A significant correlation was observed between HOMA-IR and ALT (R2=0.208; p<0.0001), as well as between HOMA-IR and AST or GGT (R2=0.112 and R2=0.080; p<0.0001). The correlation was maintained when cases with elevated enzyme levels were omitted from analysis. Diabetes and hypertriglyceridemia were the features of the MS most commonly associated with raised liver enzymes. In logistic regression, after correction for age, gender, BMI and features of the MS, HOMA-IR maintained a highly predictive value for raised ALT, AST and GGT. We conclude that in obesity insulin resistance is a risk factor for raised liver enzyme levels, possibly related to NAFLD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15966506     DOI: 10.1007/bf03347199

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  39 in total

1.  1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.

Authors: 
Journal:  J Hypertens       Date:  1999-02       Impact factor: 4.844

2.  Body fat distribution, relative weight, and liver enzyme levels: a population-based study.

Authors:  Saverio Stranges; Joan M Dorn; Paola Muti; Jo L Freudenheim; Eduardo Farinaro; Marcia Russell; Thomas H Nochajski; Maurizio Trevisan
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

3.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

4.  Prevalence of and risk factors for hepatic steatosis in Northern Italy.

Authors:  S Bellentani; G Saccoccio; F Masutti; L S Crocè; G Brandi; F Sasso; G Cristanini; C Tiribelli
Journal:  Ann Intern Med       Date:  2000-01-18       Impact factor: 25.391

5.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

6.  Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver.

Authors:  C Loguercio; T De Simone; M V D'Auria; I de Sio; A Federico; C Tuccillo; A M Abbatecola; C Del Vecchio Blanco
Journal:  Dig Liver Dis       Date:  2004-06       Impact factor: 4.088

7.  Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values.

Authors:  Pouneh Mofrad; Melissa J Contos; Mahmadul Haque; Carol Sargeant; Robert A Fisher; Velimir A Luketic; Richard K Sterling; Mitchell L Shiffman; Richard T Stravitz; Arun J Sanyal
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

8.  Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life.

Authors:  I J Hickman; J R Jonsson; J B Prins; S Ash; D M Purdie; A D Clouston; E E Powell
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

9.  Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study.

Authors:  S Bellentani; C Tiribelli; G Saccoccio; M Sodde; N Fratti; C De Martin; G Cristianini
Journal:  Hepatology       Date:  1994-12       Impact factor: 17.425

10.  The prevalence and etiology of elevated aminotransferase levels in the United States.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Am J Gastroenterol       Date:  2003-05       Impact factor: 10.864

View more
  45 in total

Review 1.  γ-Glutamyltranspeptidases: sequence, structure, biochemical properties, and biotechnological applications.

Authors:  Immacolata Castellano; Antonello Merlino
Journal:  Cell Mol Life Sci       Date:  2012-04-21       Impact factor: 9.261

Review 2.  NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes.

Authors:  Elisabetta Bugianesi; Ester Vanni; Giulio Marchesini
Journal:  Curr Diab Rep       Date:  2007-06       Impact factor: 4.810

3.  Noninvasive assessment of abdominal adipose tissues and quantification of hepatic and pancreatic fat fractions in type 2 diabetes mellitus.

Authors:  Manoj Kumar Sarma; Andres Saucedo; Christine Hema Darwin; Ely Richard Felker; Kavya Umachandran; Daniel Kohanghadosh; Edward Xu; Steve Raman; Michael Albert Thomas
Journal:  Magn Reson Imaging       Date:  2020-07-12       Impact factor: 2.546

4.  Associated liver enzymes with hyperlipidemic profile in type 2 diabetes patients.

Authors:  Noura Al-Jameil; Farah A Khan; Sadia Arjumand; Mohammad F Khan; Hajera Tabassum
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

5.  Association Between Elevated Liver Enzymes and Metabolic Syndrome Among Thai Adults.

Authors:  Sajithya Perera; Vitool Lohsoonthorn; Wiroj Jiamjarasrangsi; Somrat Lertmaharit; Michelle A Williams
Journal:  Diabetes Metab Syndr       Date:  2008-09

6.  Hepatic glucose uptake is increased in association with elevated serum γ-glutamyl transpeptidase and triglyceride.

Authors:  Sun-pyo Hong; Tae Soo Noh; Seung-Hwan Moon; Young Seok Cho; Eun Jeong Lee; Joon Young Choi; Byung-Tae Kim; Kyung-Han Lee
Journal:  Dig Dis Sci       Date:  2013-12-11       Impact factor: 3.199

7.  Normal serum aminotransferase levels and the metabolic syndrome: Korean National Health and Nutrition Examination Surveys.

Authors:  Hyeon Chang Kim; Kui Son Choi; Young Hwa Jang; Hae Won Shin; Dae Jung Kim
Journal:  Yonsei Med J       Date:  2006-08-31       Impact factor: 2.759

8.  Hypolipidemic and antioxidant effects of dandelion (Taraxacum officinale) root and leaf on cholesterol-fed rabbits.

Authors:  Ung-Kyu Choi; Ok-Hwan Lee; Joo Hyuk Yim; Chang-Won Cho; Young Kyung Rhee; Seong-Il Lim; Young-Chan Kim
Journal:  Int J Mol Sci       Date:  2010-01-06       Impact factor: 6.208

9.  Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease.

Authors:  Zhou-wen Chen; Li-ying Chen; Hong-lei Dai; Jian-hua Chen; Li-zheng Fang
Journal:  J Zhejiang Univ Sci B       Date:  2008-08       Impact factor: 3.066

Review 10.  Effect of Intragastric Balloons on Liver Enzymes: A Systematic Review and Meta-Analysis.

Authors:  Violeta B Popov; Christopher C Thompson; Nitin Kumar; Maria M Ciarleglio; Yanhong Deng; Loren Laine
Journal:  Dig Dis Sci       Date:  2016-05-20       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.